Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 5, 2013, Pages

  Shea, Beverley ^a   Swinden, Michael V ^a   Tanjong Ghogomu, Elizabeth ^a   Ortiz, Zulma ^b   Katchamart, Wanruchada ^c   Rader, Tamara ^a   Bombardier, Claire ^d   Wells, George A ^a   Tugwell, Peter ^a,e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^c MAHIDOL UNIVERSITY   (Thailand)

^d INSTITUTE FOR WORK AND HEALTH   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; FOLIC ACID; FOLINIC ACID; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; FOLIC ACID ANTAGONIST;

AMINOTRANSFERASE BLOOD LEVEL; ARTHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; JOINT SWELLING; LIVER TOXICITY; META ANALYSIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; ABDOMINAL PAIN; ADULT; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; VOMITING; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE;

ABDOMINAL PAIN; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FOLIC ACID; FOLIC ACID ANTAGONISTS; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; LEUCOVORIN; METHOTREXATE; NAUSEA; VOMITING;

EID: 84881660129     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000951.pub2     Document Type: Review

References (56)

1. Buckley L, Vacek P, Cooper S. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. Journal of Rheumatology 1990;17:1158-61.
2. Morgan SL, Baggott J, Vaughn W, Young P, Austin J, Krumdieck C, Alarcon S. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism 1990;33(1):9-18.
3. Morgan S, Baggot J, Vaughn W, et al.Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo controlled trial. Annals of Internal Medicine 1994;121(11):833-41.
4. Shiroky J, Neville C, Esdaile J, et al.Low dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a randomized, double-blind, placebo controlled trial. Arthritis and Rheumatism 1993;36(3):795-803.
5. Van Ede A, Laan R, Blom H, Huizinga T, Haagsma C, Giesendorf B, et al.The C677T mutation in the methylenetetrahydrofolate reductase gene. A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis and Rheumatism 2001;44(11):2525-30.
6. Weinblatt M, Maier A, Coblyn J. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 weeks randomized placebo controlled trial. Journal of Rheumatology 1993;20:950-2.
7. Andersen LS, Hansen EL, Knusdsen JB, Wester JU, Hansen GVO, Hansen TM. Propectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: Relation to withdrawal and side effects. Journal of Rheumatology 1997;24(5):830-7.
8. The Canadian Leucovorin Study Group. Low dose methotrexate with leucovorin in the management of rheumatoid arthritis [Abstract]. Arthritis and Rheumatism 1993;36(6):795-803.
9. Griffith S, Fisher J, Clarke S, Montgomery B, Jones P, Saklatvala J, et al.Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?. Rheumatology 2000;39:1102-9.
10. Hanrahan P, Russell A. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. Journal of Rheumatology 1988;15:1078-80.
11. Joyce D, Will D, Hoffman D, Laing B, Blackbourn S. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Annals of the Rheumatic Diseases 1991;50:913-4.
12. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention. Journal of Rheumatology 1998;25:441-6.
13. Stewart K, Mackenzie A, Clough J, Wilke W. Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Seminars in Arthritis and Rheumatism 1991;20(5):332-8.
14. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis and Rheumatism 1988;31(7):906-8.
15. Weinblatt M, Maier A, Coblyn J. Low dose leucovorin plus methotrexate (MTX) in rheumatoid arthritis (RA): an eight week placebo controlled randomized trial [Abstract]. Arthritis and Rheumatism 1992;Suppl:S340.
16. Andersen P, West S, O'Dell J, et al.Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Annals of Internal Medicine 1985;103:489-96.
17. Arnett F, Edworthy S, Bloch D, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315-24.
18. Brooks P, Day R. Toxicity of antirheumatic drugs. Journal of Rheumatology 1995;22(5):998-90.
19. Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, et al.BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008;47(6):924-5. [PUBMED: 16940305]
20. Deeks JJ, Higgins JPT, Altman DG (editors). The Cochrane Collaboration, 2011 . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
22. Dijkmans B. Folate supplementation and methotrexate. British Journal of Rheumatology 1995;34:1172-4.
23. Drummond M, Bosi Ferraz M, Mason J. Assessing the cost effectiveness of NSAID: an international perspective. Journal of Rheumatology 1995;22(7):1408-14.
24. Dutch Society of Rheumatology. Guidelines for Medication: Methotrexate [Nederlandse Vereniging voor Reumatologie. Richtlijnen Medicijnen: Methotrexaat]. Available via http://www.nvr.nl/richtlijnen/Totstandkoming_richtlijnen September 2009 (Updated 2011).
25. Felson D, Anderson J, Meenan R. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis and Rheumatism 1990;33(10):1449-61.
26. Felson D, Anderson J, Meenan R. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A meta-analysis of published clinical trials. Arthritis and Rheumatism 1992;35:1117-25.
27. Furst D, Clements P. Pharmacological approaches. SAARDs- II. Rheumatology 1994;13:1-8.
28. GUIPCAR Group. Clinical practice guideline for the management of rheumatoid arthritis in Spain. Spanish Society of Rheumatology, Madrid 2007:301.
29. Hartman M, VanEde AE, Severens JL, Laan R, van de Putte L, van der Wilt G. Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis. Journal Of Rheumatology 2004;31(5):902-8.
30. Hedges LV. Estimation of effect size from a series of independent experiments. Psychological Bulletin 1982;92:490-499.
31. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
32. Jackson R. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacology & Therapeutics 1984;25:61-82.
33. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010;4:pp CD008495.
34. Kremer J, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis and Rheumatism 1986;29:832-4.
35. Kremer J. The changing face of therapy for rheumatoid arthritis. Rheumatic Diseases Clinics of North America 1995;21(3):845-52.
36. Leeb BF, Witzmann G, Ogris E, Studnicka-Benke A, Andel I, Schweitzer H, Smolen JS. Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clinical and Experimental Rheumatology 1995 Jul-Aug;13(4):459-63.
37. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. American Journal of Medicine 2007;120 (11):36-9.
38. Maxwell L, Singh J. Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009;4:pp CD007277.
39. Morgan S, Baggot J, Altz-Smith M. Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy. Arthritis and Rheumatism 1987;30:1348-56.
40. Morgan S, Baggot J, Refsum H, Ueland P. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clinical Pharmacology and Therapeutics 1991;50:547-56.
41. Morgan S, Alarcón G, Krumdieck C. Folic acid supplementation during methotrexate therapy: it makes sense [Editorial]. Journal of Rheumatology 1993;20(6):929-30.
42. Navarro Sabia F, Ariza Ariza R, Hernandez Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2]
43. Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. First Edition. New York: Oxford University Press, 1994:90-114.
44. Salach R, Cash J. Methotrexate: The emerging drug of choice for serious rheumatoid arthritis. Clinical Therapeutics 1994;16(6):912-22.
45. Schnabel A, Gross Wl. Low-dose methotrexate in rheumatic diseases: efficacy, side effects and risk factors for side effects. Seminars in Arthritis and Rheumatism 1994;23:310-27.
46. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
47. Singh J, Christensen R, Wells G, Suarez Alamor M, Buchbinder R, Lopez Olivo A, Tanjong Ghogomu E, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2]
48. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care and Research May 2012;64(5):625-39. [PUBMED: 22473917]
49. Stenger A, Houtman P, Bruyn G. Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate?. Annals of the Rheumatic Diseases 1992;51:1019-20.
50. Suarez-Almazor ME, Belseck E, Shea B, Tugwell P, Wells GA. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD000957]
51. Thompson R, Watts C, Edelman J, et al.A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. Journal of Rheumatology 1984;11:760-3.
52. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Annals of Internal Medicine 1987;107:358-66.
53. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines. Annals of Internal Medicine 1989;110:581-3.
54. Wallace C, Sherry D. A practical to avoidance of methotrexate toxicity [Editorial]. Journal of Rheumatology 1995;22(6):1009-12.
55. Weinblatt M, Coblyn J, Fox D, et al.Efficacy of low-dose methotrexate in rheumatoid arthritis. New England Journal of Medicine 1985;312:818-22.
56. Williams H, Wilkens R, Samuelson C, et al.Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism 1985;28:721-30.